MedTrace Logo

The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency

NCT06117982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-05-08

No results posted yet for this study

Summary

The goal of this pilot study is to improve ovarian reserve markers in patients with premature ovarian insufficiency. The main question it aims to answer is:

\- Will treatment with G-CSF allow improvement in markers of ovarian reserve?

Conditions

  • Primary Ovarian Insufficiency
  • Premature Ovarian Failure

Interventions

DRUG

Neupogen

Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days

Sponsors & Collaborators

  • Trio Fertility

    lead OTHER

Principal Investigators

  • Robert F. Casper, Dr. · Trio Fertility, Toronto, ON, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-13
Primary Completion
2025-05-01
Completion
2025-05-01
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06117982 on ClinicalTrials.gov